Vitamin D Supplementation in the Prevention of Hip Fractures in the Elderly Population
Methods: A literature search was performed using the PubMed and Cochrane Library databases. Fifteen pertinent studies were identified and reviewed.
Results: Vitamin D supplementation, in low doses and alone, did not appear to diminish fracture risk. However, vitamin D at doses above 700 IU daily, especially when combined with calcium, demonstrated an association with decreased risk of fracture. Some studies found significantly diminished fracture rates at doses between 800 and 2000 IU. These findings were most pronounced in institutional settings, which may relate to compliance to the treatment. In addition, vitamin D supplementation appears to be safe at the levels tested.
Conclusion: The conclusion is that vitamin D oral supplementation at higher doses of at least 700-800 IU daily, particularly in combination with calcium supplementation, may be preventive for those older individuals at risk for fracture. These results may have significant benefit from a public health perspective.
Learning Areas:Chronic disease management and prevention
Clinical medicine applied in public health
Other professions or practice related to public health
Planning of health education strategies, interventions, and programs
Provision of health care to the public
Public health or related education
Explain the physiology of vitamin D in fracture prevention. Differentiate the effects of low dose vitamin D versus higher dose vitamin D on fracture prevention. Discuss the role of supplementation of vitamin D in fracture prevention in both institutionalized and non-institutionalized adults.
Keyword(s): Chronic Disease Prevention, Aging
Qualified on the content I am responsible for because: I have presented and published on the topic of osteoporosis in the past. I also am board certified in nutrition, as well as being a doctor of chiropractic and on the faculty of Palmer College Florida.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.